STRIVE 2
The STRIVE 2 study is evaluating the investigational Omnipod 6 Automated Insulin Delivery System compared with the Omnipod 5 System in adolescents and adults with Type 1 or Type 2 Diabetes.
Who May Qualify
Individuals ages 14–75 with Type 1 Diabetes or Type 2 Diabetes meeting study requirements.
Technology
Evaluate the next-generation Omnipod 6 Automated Insulin Delivery System.
Timeline
Approximately 30–34 weeks including screening, treatment periods, and extension.
Benefits
Gain access to investigational diabetes technology while contributing to future diabetes care.
Study Overview
The STRIVE 2 study is evaluating the investigational Omnipod 6 Automated Insulin Delivery System compared with the Omnipod 5 System to determine whether enhanced glucose management features improve outcomes for people living with diabetes.
What Participation Looks Like
- Screening assessments
- Dexcom G7 Continuous Glucose Monitor
- Two-week standard therapy period
- Two 13-week treatment periods
- Scheduled clinic and virtual visits
- Questionnaires and optional meal challenges
Important Considerations
Participation is voluntary. Study staff will review eligibility requirements, potential risks, compensation, and study-related costs during the informed consent process.
Interested in Participating?
Our research team is available to answer your questions and determine whether this study may be a good fit for you.
Contact the Study Team